Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

All the vital news, analysis, and commentary curated by our industry experts.

$14995

Buy Report

Published: December 27, 2024 Report Code: GDHC302PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the type 1 diabetes market through 2033.

GlobalData estimates sales of T1D therapeutics to be approximately $2.83 billion across the 7MM in 2023. By 2033, GlobalData expects the T1D market to grow at a strong compound annual growth rate (CAGR) of 13.3%, reaching sales of $9.91 billion by the end of the forecast period.

Major drivers of T1D market growth over the forecast period are the:
• Increase in the prescription of rapid-acting insulins in line with rising use of insulin pumps
• Launch of several oral and injectable agents, particularly immunomodulatory therapies
• Increase in the global prevalence of T1D

Major barriers that will restrict the growth of the T1D market during the forecast period are the:
• High price of certain insulins and immunomodulatory agents
• Patent expiries allowing for further biosimilar and generic erosion
• High failure rate of clinical trials developing disease-modifying therapeutics

Scope

Overview of type 1 diabetes, including epidemiology, symptoms, diagnosis, and disease management.

Annualized type 1 diabetes therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the type 1 diabetes therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for type 1 diabetes treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global type 1 diabetes therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM type 1 diabetes therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM type 1 diabetes therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Novo Nordisk
Eli Lilly
Sanofi
AstraZeneca
Boehringer Ingelheim
Lexicon
Fujifilm
Novartis
CellTrans
Merck
Dompe Pharmaceuticals
Astellas Pharma
Diamyd Medical
Amgen
vTv Therapeutics
Bristol Myers Squibb
Adocia
Janssen Pharmaceuticals
Johnson & Johnson

List of Contents

List of Tables

List of Figures

1 Type 1 Diabetes: Executive Summary

1.1 Type 1 Diabetes therapeutics market will grow to $9.91 billion by 2033

1.2 T1D market leaders employ diverse strategies to protect insulin franchises from biosimilar threats, while emerging players focus on disease-modifying innovations

1.3 Persistent unmet needs highlight gaps in current and emerging T1D therapies

1.4 The synergistic rise of pumps, CGMs, and ultra-rapid-acting insulins in T1D management

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Biomarkers for monitoring the islet autoreactivity of T1D

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of T1D – 7MM

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of T1D

4.4.5 Diagnosed prevalent cases of T1D segmented by BMI

4.4.6 Diagnosed prevalent cases of T1D that experienced hypoglycemic events

4.4.7 Diagnosed prevalent cases of T1D with brittle diabetes

4.4.8 Diagnosed prevalent cases of T1D that experienced DKA events

4.4.9 Diagnosed prevalent cases of T1D eligible for pancreas transplantation

4.4.10 Diagnosed prevalent cases of T1D with CKD

4.4.11 Diagnosed prevalent cases of T1D with CVD

4.4.12 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8

4.4.13 Forecast assumptions and methods: total prevalent cases of T1D

4.5 Epidemiological forecast for T1D (2023–33)

4.5.1 Diagnosed prevalent cases of T1D

4.5.2 Age-specific diagnosed prevalent cases of T1D

4.5.3 Sex-specific diagnosed prevalent cases of T1D

4.5.4 Diagnosed prevalent cases of T1D by BMI category

4.5.5 Diagnosed prevalent cases of T1D that experienced hypoglycemic events

4.5.6 Diagnosed prevalent cases of T1D with brittle diabetes

4.5.7 Diagnosed prevalent cases of T1D that experienced DKA events

4.5.8 Diagnosed prevalent cases of T1D eligible for pancreas transplantation

4.5.9 Diagnosed prevalent cases of T1D with CKD

4.5.10 Diagnosed prevalent cases of T1D with CVD

4.5.11 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA–DQ8

4.5.12 Total prevalent cases of T1D

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 US disease management

5.3 5EU disease management

5.4 Japan disease management

5.5 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Urgent need for disease-modifying therapies

7.3 Avoiding hypoglycemic episodes and optimising glycemic control

7.4 Improving compliance and reducing the burden of insulin therapy

7.5 High financial cost of T1D management

8 R&D Strategies

8.1 Overview

8.1.1 Immunomodulatory therapies: addressing autoimmune pathogenesis

8.1.2 Advanced drug delivery systems and glucose-responsive insulins

8.1.3 Regenerative medicine: pursuing curative therapies

8.2 Clinical trials design

8.2.1 Study design – adaptive clinical trials and comprehensive frameworks

8.2.2 Digital health integration

8.2.3 Model-based simulations

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

10.2.1 Insulin therapies

10.2.2 Non-insulin therapies

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Vice President of Disease Intelligence and Epidemiology

13.6.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: Type 1 Diabetes: key metrics in the 7MM

Table 2: Symptoms of T1D

Table 3: Diagnostic tests commonly used for T1D

Table 4: Risk factors and comorbidities for T1D

Table 5: Diagnostic tests and typical criteria for diagnosing T1D

Table 6: Treatment guidelines for T1D

Table 7: Top 10 deals by value, 2019–24

Table 8: T1D market – global drivers and barriers, 2023–33

Table 9: Key events impacting sales for T1D in the US, 2023–33

Table 10: T1D market – drivers and barriers in the US, 2023–33

Table 11: Key events impacting sales for T1D in the 5EU, 2023–33

Table 12: T1D market – drivers and barriers in the 5EU, 2023–33

Table 13: Key events impacting sales for T1D in Japan, 2023–33

Table 14: T1D market – drivers and barriers in Japan, 2023–33

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for T1D in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in T1D during the forecast period

Figure 3: Competitive assessment of the late-stage insulin and non-insulin treatments that GlobalData expects to be licensed for the treatment of T1D during the forecast period

Figure 4: Etiology of T1D

Figure 5: Pathophysiology of T1D

Figure 6: 7MM, diagnosed prevalence of T1D, men and women, %, all ages, 2023

Figure 7: 7MM, total prevalence of T1D, men and women, %, all ages, 2023

Figure 8: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of T1D segmented by BMI category

Figure 10: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D that experienced hypoglycemia

Figure 11: 7MM, source used to forecast the diagnosed prevalent cases of T1D with brittle diabetes

Figure 12: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D that experienced DKA

Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of T1D that are eligible for a pancreas transplant

Figure 14: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D with CKD

Figure 15: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D with CVD

Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8

Figure 17: 7MM, sources used to forecast the total prevalent cases of T1D

Figure 18: 7MM, diagnosed prevalent cases of T1D, N, both sexes, all ages, 2023

Figure 19: 7MM, diagnosed prevalent cases of T1D by age, N, both sexes, 2023

Figure 20: 7MM, diagnosed prevalent cases of T1D by sex, N, all ages, 2023

Figure 21: 7MM, diagnosed prevalent cases of T1D by BMI category, N, both sexes, all ages, 2023

Figure 22: 7MM, diagnosed prevalent cases of T1D that experienced hypoglycemic events, N, both sexes, all ages, 2023

Figure 23: 7MM, diagnosed prevalent cases of T1D with brittle diabetes, N, both sexes, all ages, 2023

Figure 24: 7MM, diagnosed prevalent cases of T1D that experienced DKA, N, both sexes, all ages, 2023

Figure 25: 7MM, diagnosed prevalent cases of T1D eligible for pancreas transplantation, N, both sexes, ≥20 years,

Figure 26: 7MM, diagnosed prevalent cases of T1D with CKD, N, both sexes, all ages, 2023

Figure 27: 7MM, diagnosed prevalent cases of T1D with CVD, N, both sexes, all ages, 2023

Figure 28: 7MM, diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8, N, both sexes, all ages, 2023

Figure 29: 7MM, total prevalent cases of T1D, N, both sexes, all ages, 2023

Figure 30: Disease management flow chart

Figure 31: Unmet needs and opportunities in T1D

Figure 32: Overview of the development pipeline in T1D

Figure 33: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for T1D in the 7MM during the forecast period

Figure 34: Competitive assessment of the pipeline insulin therapies benchmarked against the standard of care (SOC), Novolog (insulin aspart)

Figure 35: Competitive assessment of the pipeline non-insulin therapies benchmarked against the standard of care (SOC), Tzield (teplizumab)

Figure 36: Analysis of the company portfolio gap in T1D during the forecast period

Figure 37: Global (7MM) sales forecast by country for T1D in 2023 and 2033

Figure 38: Sales forecast by class for T1D in the US in 2023 and 2033

Figure 39: Sales forecast by class for T1D in the 5EU in 2023 and 2033

Figure 40: Sales forecast by class for T1D in Japan in 2023 and 2033

Frequently asked questions

Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports

Currency USD

Single User

$14,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Type 1 Diabetes (Juvenile Diabetes) reports

Pharmaceuticals

New

Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline…

Pharmaceuticals

New

Catalyst Monitor: Q2 2026 Outlook

Pharmaceuticals

New

Emerging Market Outsourcing Report, Q1 2026

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

Access a live Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Scope

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports